Yonsei Med J. 2004 Oct;45(5):818-821. English.
Published online Feb 17, 2009.
Copyright © 2004 The Yonsei University College of Medicine
Original Article

Mutations of the BRAF Gene in Papillary Thyroid Carcinoma in a Korean Population

Kyung Hee Kim,1 Dong Wook Kang,1 Seong Ho Kim,1 In Ock Seong,1 and Dae Young Kang2
    • 1Department of Pathology, Eulji University School of Medicine, Daejeon, Korea.
    • 2Department of Pathology, College of Medicine, Chungnam National University, Daejeon, Korea.
Received June 17, 2004; Accepted July 30, 2004.

Abstract

The B-type Raf kinase (BRAF) protein is a serine/threonine kinase that has an important role in cellular proliferation, differentiation, and programmed cell death. The BRAF gene has been recently found to be mutated in human carcinomas, predominantly in malignant melanoma. The aim of this study was to investigate the frequency of the BRAF mutation in papillary thyroid carcinoma (PTC) of Koreans through direct DNA sequencing of the polymerase chain reaction (PCR) - amplified exon 15 with clinicopathological features. Seventy paraffin-embedded conventional papillary carcinomas in the thyroid gland were evaluated. The BRAF missense mutation at V599E was found in 58 of 70 PTCs (83%). The frequency of our series was much higher than the frequencies of other PTC series (36 - 69%). The frequency of nodal metastasis was also significantly higher in the BRAF mutation group (p=0.048). These results suggest that the BRAF mutation is involved in the carcinogenesis in most conventional PTCs, especially those occurring in Koreans, and this is a potentially valuable marker for the evaluation of prognosis of patients with PTC. These findings support the specific inhibitors of BRAF being promising targets for the disease outcome.

Keywords
BRAF protein; mutation; papillary carcinoma; thyroid gland


Metrics
Share
PERMALINK